

+

+

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

JUN 12 2002

Complete if Known

Application Number	09/996,738
Filing Date	30 November 2001
First Named Inventor	Philip Gotwals
Group Art Unit	1614 1644
Examiner Name	Unknown
Attorney Docket Number	A076 IIS

(use as many sheets as necessary)

Sheet

4

of

2

Attorney Docket Number

A076 US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Maheer Hagelstad

Date _____

Considered	Not considered
<p>1. The number of people who have been vaccinated against COVID-19.</p> <p>2. The number of people who have been tested for COVID-19.</p> <p>3. The number of people who have been hospitalized with COVID-19.</p> <p>4. The number of people who have died from COVID-19.</p> <p>5. The number of people who have been in contact with someone who has been infected with COVID-19.</p> <p>6. The number of people who have been in contact with someone who has been hospitalized with COVID-19.</p> <p>7. The number of people who have been in contact with someone who has died from COVID-19.</p> <p>8. The number of people who have been in contact with someone who has been in contact with someone who has been infected with COVID-19.</p> <p>9. The number of people who have been in contact with someone who has been in contact with someone who has been hospitalized with COVID-19.</p> <p>10. The number of people who have been in contact with someone who has been in contact with someone who has died from COVID-19.</p>	<p>1. The number of people who have been vaccinated against COVID-19.</p> <p>2. The number of people who have been tested for COVID-19.</p> <p>3. The number of people who have been hospitalized with COVID-19.</p> <p>4. The number of people who have died from COVID-19.</p> <p>5. The number of people who have been in contact with someone who has been infected with COVID-19.</p> <p>6. The number of people who have been in contact with someone who has been hospitalized with COVID-19.</p> <p>7. The number of people who have been in contact with someone who has died from COVID-19.</p> <p>8. The number of people who have been in contact with someone who has been in contact with someone who has been infected with COVID-19.</p> <p>9. The number of people who have been in contact with someone who has been in contact with someone who has been hospitalized with COVID-19.</p> <p>10. The number of people who have been in contact with someone who has been in contact with someone who has died from COVID-19.</p>

10/28/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/996,738
Filing Date	30 November 2001
First Named Inventor	Philip Gotwals
Group Art Unit	1644 1614
Examiner Name	Unknown
Attorney Docket Number	A076 US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mt	CA	Briesewitz et al., 1993, Journal of Biological Chemistry, 268:2989-2996, "Expression of Native and Truncated Forms of the Human Integrin α 1 Subunit"	
mt	CB	Fabbri et al, 1996, Tissue Antigens, 48:47-51, "A functional monoclonal antibody recognizing the human α 1b1-integrin I-domain"	
mt	CC	Gotwals, et al, 1999, Biochemistry 38:8280-8288, "Divalent Cations Stabilize the α 1b1 Integrin I Domain"	
mt	CD	Kern et al., 1994, Journal of Biological Chemistry, 269:22811-22816, "The Role of the I Domain in Ligand Binding of the Human Integrin α 1b1"	
mt	CE	Laffon et al, 1989 Arthritis and Rheumatism 32:386-392, "Very Late Activation Antigen of Synovial Fluid T cells from Patients with Rheumatoid Arthritis and other Rheumatic Diseases"	

Examiner Signature	Maker Hagedorn	Date Considered	10/23/02
--------------------	----------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.